Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print

/PRNewswire/ -- BIOXYTRAN, INC. (OTCQB: BIXT), (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...

Related Keywords

Boston ,Massachusetts ,United States ,Michael Sheikh ,Alben Sigamani ,Hana Chen Walden ,Nuclear Magnetic Resonance ,Bioxytran Inc ,Galectin Antagonist ,Magnetic Resonance ,N Terminal Domain ,Bioxytran Medical Advisory Board ,Medical Director ,Bioxytran ,Nc ,